Patents Assigned to Erasmus University Medical Center
-
Patent number: 10531818Abstract: Method and instrument for analysing a tissue sample. Localized concentrations of an analyte are measured at a plurality of spaced apart locations around a controlled depth. Spatial variance of the analyte is calculated based on the measured analyte concentrations. The procedure is repeated while varying the controlled depth to obtain the spatial variance as a function of depth. Tissue at a particular depth may be evaluated as tumour tissue when the spatial variance is below the threshold. For example, a section distance is calculated between the tissue surface and a depth where the measured spatial variance crosses a predetermined threshold variance. Feedback can be provided based on a comparison between a calculated section distance and a pre-set minimum section margin.Type: GrantFiled: January 18, 2016Date of Patent: January 14, 2020Assignee: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAMInventors: Gerwin Jan Puppels, Elisa Maria Barroso, Tom Christian Bakker Schut, Roeland W. H. Smits, Peter Jacobus Caspers, Senada Koljenovic
-
Patent number: 10519517Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.Type: GrantFiled: December 28, 2018Date of Patent: December 31, 2019Assignees: VIRONOVATIVE BV, ERASMUS UNIVERSITY MEDICAL CENTERInventors: Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Groen
-
Publication number: 20190383817Abstract: The present disclosure relates to methods and kits for classifying an individual afflicted with multiple myeloma based on the likelihood of response to immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide. The disclosure further relates to methods of treating an individual afflicted with multiple myeloma with an IMiD and with methods for determining a therapy regime based on the likelihood of response to an IMiD as a result of genetic characteristic of the patient.Type: ApplicationFiled: February 9, 2017Publication date: December 19, 2019Applicants: SKYLINEDX B.V., ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAMInventors: Pieter SONNEVELD, Martinus Hendrikus VAN VLIET, Cornelia Maria DE BEST
-
Patent number: 10442858Abstract: Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors.Type: GrantFiled: September 21, 2017Date of Patent: October 15, 2019Assignees: Erasmus University Medical Center, Surface Oncology, Inc.Inventors: Frank Grosveld, Scott Chappel, Jonathan Hill, Pamela M. Holland, Andrew Lake, Alison Paterson
-
Patent number: 10308940Abstract: The present invention is directed to antisense oligomeric compounds that may be used in the treatment Pompe disease as well as method for modulating the splicing of the GAA gene and method to treat Pompe disease. Also pharmaceutical compositions comprising the antisense oligomeric compounds are part of the invention.Type: GrantFiled: June 10, 2015Date of Patent: June 4, 2019Assignee: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAMInventors: Atze Jacobus Bergsma, Erik van der Wal, Wilhelmus Wenceslaus Matthias Pijnappel, Antje Tjitske van der Ploeg, Arnoldus Reuser
-
Patent number: 10287640Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.Type: GrantFiled: March 29, 2018Date of Patent: May 14, 2019Assignee: Erasmus University Medical Center RotterdamInventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Cornelius De Jong, Jan Groen
-
Patent number: 10209245Abstract: The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least there identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.Type: GrantFiled: December 20, 2017Date of Patent: February 19, 2019Assignee: Erasmus University Medical Center RotterdamInventors: Jacobus Johannes Maria van Dongen, Jose Alberto Orfao de Matos Correia e Vale, Juan Alejandro Flores-Montero, Julia Maria Almeida Parra, Vincent Henricus Johannes van der Velden, Sebastian Böttcher, Andrew Craig Rawstron, Ruth Mary de Tute, Ludovic Bernard Simon Lhermitte, Vahid Asnafi, Ester Mejstrikova, Tomasz Szczepanski, Paulo Jorge Monteiro Da Silva Lucio, Marta Martín Ayuso, Carlos Eduardo Pedreira
-
Patent number: 10167524Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.Type: GrantFiled: October 27, 2017Date of Patent: January 1, 2019Assignee: Erasmus University Medical Center RotterdamInventors: Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Groen
-
Patent number: 10041953Abstract: The invention relates to a method to determine drug resistance in microbes. The method relates to measuring the drug resistance conferring protein by mass spectrometry. The mass spectrum acquired provides information whether an drug resistance conferring protein is present and information on the type of drug resistance conferring protein, on mutations of the drug resistance conferring protein as well as on the expression level of this protein.Type: GrantFiled: April 4, 2013Date of Patent: August 7, 2018Assignee: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAMInventors: Theo Marten Luider, Wilhelmus Hubertus Francisus Goessens
-
Publication number: 20180216200Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.Type: ApplicationFiled: March 29, 2018Publication date: August 2, 2018Applicant: Erasmus University Medical Center RotterdamInventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Cornelius De Jong, Jan Groen
-
Publication number: 20180187190Abstract: The present invention relates to expression vectors harboring eukaryotic CRISPR sequences and their use in assays to study the intervention of eukaryotic CRISPR sequences with gene regulation and with gene editing in eukaryotes using CRISPR-Cas technology.Type: ApplicationFiled: June 10, 2016Publication date: July 5, 2018Applicant: Erasmus University Medical Center RotterdamInventor: Rogier Petrus Leonardus LOUWEN
-
Patent number: 9980470Abstract: A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge.Type: GrantFiled: March 14, 2014Date of Patent: May 29, 2018Assignee: Erasmus University Medical CenterInventors: Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Marinus Johannes Van Haperen, Roger Kingdon Craig, Ernie De Boer
-
Patent number: 9976185Abstract: The present invention is in the field of molecular diagnostics and relates to a method for classifying samples obtained from patients diagnosed with multiple myeloma into three newly defined clusters. The invention also relates to a method for determining the prognosis of an individual diagnosed with multiple myeloma as well as a method for the prediction of the response to treatment of an individual diagnosed with multiple myeloma. More in particular, the invention provides a method for determining the disease outcome or the prognosis of a patient diagnosed with multiple myeloma by classifying said patient into a high risk or a low risk category, based on a 92 gene classifier.Type: GrantFiled: July 12, 2012Date of Patent: May 22, 2018Assignee: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAMInventors: Rowan Kuiper, Pieter Sonneveld
-
Publication number: 20180137621Abstract: A method is disclosed for analysing an image to assess a condition of an organ of a patient represented in the image. The method includes initially selecting a spatial resolution for an inspection matrix having a number of inspection regions each delimiting a part of the image. The inspection matrix is applied to the image and the part of the image within each of the inspection regions is analysed to determine a condition thereof. The condition is compared with a predetermined criterion and, if the condition is deemed to satisfy the criterion, the inspection region is identified, e.g. by annotating it with a colour. Finally a quantitative measure of an extent of the condition in the image is provided that is based on a number of the identified or annotated inspection regions.Type: ApplicationFiled: March 9, 2016Publication date: May 17, 2018Applicants: Telethon Kids Institute, Erasmus University Medical Center RotterdamInventors: Stephen Stick, Tim Rosenow, Harmannus Arnoldus Wilhelmus Maria Tiddens, Marleen De Bruijne
-
Patent number: 9962127Abstract: A catheter-based optical imaging system for imaging a patient includes a catheter-based imaging device configured to direct optical radiation towards a vessel wall and to receive reflected radiation therefrom. A displacement mechanism is configured to vary the position of the imaging device relative to the catheter as a function of time during an imaging scan. An input is configured to receive cardiac event timing data, such as ECG data, from the patient. A trigger module is configured to initiate an imaging scan based on the cardiac event timing obtained from the cardiac event timing data. By triggering the optical imaging scans between cardiac events, artifacts in the image data can be reduced or eliminated.Type: GrantFiled: March 17, 2014Date of Patent: May 8, 2018Assignee: Erasmus University Medical Center RotterdamInventors: Tianshi Wang, Charles Theodoor Lancee, Antonius Franciscus Wilhelmus Van Der Steen, Gijs Van Soest
-
Patent number: 9944997Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.Type: GrantFiled: November 6, 2017Date of Patent: April 17, 2018Assignee: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAMInventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Cornelius De Jong, Jan Groen
-
Publication number: 20180057894Abstract: Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences.Type: ApplicationFiled: November 6, 2017Publication date: March 1, 2018Applicant: Erasmus University Medical Center RotterdamInventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Cornelius De Jong, Jan Groen
-
Publication number: 20180057893Abstract: The invention relates to the field of virology. The invention provides an isolated essentially mammalian negative-sense single-stranded RNA virus (MPV) within the subfamily Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus and components thereof.Type: ApplicationFiled: October 27, 2017Publication date: March 1, 2018Applicant: Erasmus University Medical Center RotterdamInventors: Jan Cornelius De Jong, Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Groen
-
Patent number: 9901081Abstract: This invention provides a transgenic mouse with a p16INK4a promoter sequence that controls expression of a protein such that it is expressed preferentially in senescent cells. The protein either directly induces apoptosis, or converts a prodrug to a cytotoxic compound. In addition, the mouse is injected with syngeneic tumor cells, or has second transgene that causes tumors to form. Removing senescent cells from the mouse may result in the formation of fewer tumors.Type: GrantFiled: March 25, 2016Date of Patent: February 27, 2018Assignees: Buck Institute for Research on Aging, Erasmus University Medical Center RotterdamInventors: Judith Campisi, Marco Demaria, Francis Rodier, Remi-Martin Laberge, James Mitchell, Jan H. J. Hoeijmakers, Wendy Toussaint
-
Patent number: 9901080Abstract: This invention provides a transgenic mouse for studying the role of senescent cells on an age-related disorder or an age-sensitive trait. The transgene contains a p16 promoter sequence that controls expression of an enzyme so as to cause the enzyme to be expressed in senescent cells in the mouse. The enzyme converts a prodrug to a cytotoxic agent, so that treating the mouse with the prodrug results in the prodrug selectively killing the senescent cells. As a result, progression of an age-related disorder or an age-sensitive trait is delayed. Included is the 3MR mouse model, which also expresses bioluminescent and fluorescent markers under control of the p16 promoter so that senescent cells in the mice can be visualized.Type: GrantFiled: March 11, 2016Date of Patent: February 27, 2018Assignees: Buck Institute for Research on Aging, Erasmus University Medical Center RotterdamInventors: Judith Campisi, Marco Demaria, Remi-Martin Laberge, Francis Rodier, James Mitchell, Jan H. J. Hoeijmakers, Wendy Toussaint